Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 59

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 59
---
 a lower transaction fee and a higher percentage of CVR proceeds, among other factors, and their recommendation to proceed with exclusive negotiations with XRC. After
receiving the update, the Board unanimously accepted the recommendation and authorized the Transaction Committee and management, with the assistance and advice of its financial and legal advisors, to negotiate definitive agreements for a business
combination with XRC substantially on the terms presented to the Board.

Between September 19, 2025 and October 31, 2025, XRC
and Parent discussed the possible transaction with the Company, including with XRC serving as guarantor and structuring agent, similar to other recent transactions.

On November 3, 2025, members of management and representatives of Stikeman and Cooley held a meeting to discuss the terms of the
Agreement.

On November 5, 2025, Company management and representatives of Stikeman and Cooley provided a draft of the Agreement to
Gibson Dunn.

On November 8, 2025, Gibson Dunn provided representatives of Stikeman and Cooley a draft of the CVR Agreement.

From November 5 to November 13, XRC (in consultation with Parent), members of management and representatives of Gibson Dunn,
Stikeman and Cooley had various discussions regarding the terms of the Agreement and the CVR Agreement and exchanged several drafts of such agreements. In particular, revisions were made to the CVR Agreement such that the Shareholders would receive
100% of the net proceeds of a disposition of RP-3467 to counterparties engaged prior to Closing or proceeds received on account of certain investment tax credits, tax reimbursements or refunds, to the
attributable to the period prior to the Closing.

On November 13, 2025, the Transaction Committee held a meeting, also attended by
members of management and representatives of Stikeman, Cooley and Leerink Partners to discuss the status of the draft agreements and the timeline for finalizing agreements. Representatives of Stikeman and Cooley discussed the proposed changes to the
transaction documents with the Transaction Committee.

On November 14, 2025, the Transaction Committee held a meeting, also attended
by the other members of the Board, members of management and representatives of Stikeman, Cooley and Leerink Partners. Representatives of Leerink Partners, at the request of the Transaction Committee, reviewed with the Transaction Committee Leerink
Partners’ analysis of the financial terms of the transaction, and rendered to the Transaction Committee an oral opinion